MD Anderson Cancer Center and Boehringer Ingelheim announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma.
The collaboration will focus on identifying and developing therapeutic concepts in novel target areas as well as identification of biomarkers that can accurately identify patients who would respond to potential new therapies.
“This partnership is a perfect match because it combines MD Anderson’s outstanding capabilities in preclinical concept validation and clinical testing with Boehringer Ingelheim’s strength in developing innovative medicines,” said Clive Wood, senior corporate vice president of Discovery Research at Boehringer Ingelheim.
